Literature DB >> 18479331

Cardiac resynchronization therapy upregulates cardiac autonomic control.

Yong-Mei Cha1, Jae Oh, Chinami Miyazaki, David L Hayes, Robert F Rea, Win-Kuang Shen, Samuel J Asirvatham, Brad J Kemp, David O Hodge, Peng-Sheng Chen, Panithaya Chareonthaitawee.   

Abstract

OBJECTIVE: To determine the effect of cardiac resynchronization therapy (CRT) on sympathetic nervous function in heart failure (HF).
BACKGROUND: Neurohormonal dysregulation and cardiac autonomic dysfunction are associated with HF and contribute to HF progression and its poor prognosis. We hypothesized that mechanical resynchronization improves cardiac sympathetic function in HF.
METHODS: Sixteen consecutive patients receiving CRT for advanced cardiomyopathy and 10 controls were included in this prospective study. NYHA class, 6-minute walk distance, echocardiographic parameters, plasma norepinephrine (NE) were assessed at baseline, 3-month and 6-month follow-up. Cardiac sympathetic function was determined by (123)iodine metaiodobenzylguanidine ((123)I-MIBG) scintigraphy and 24-hour ambulatory electrocardiography.
RESULTS: Along with improvement in NYHA class (3.1 +/- 0.3 to 2.1 +/- 0.4, P < 0.001) and LVEF (23 +/- 6% to 33 +/- 12%, P < 0.001), delayed heart/mediastinum (H/M) (123)I-MIBG ratio increased significantly (1.8 +/- 0.7 to 2.1 +/- 0.6, P = 0.04) while the H/M (123)I-MIBG washout rate decreased significantly (54 +/- 25% to 34 +/- 24%, P = 0.01) from baseline to 6-month follow-up. The heart rate variability (HRV) measured in SD of normal-to-normal intervals also increased significantly from baseline (82 +/- 30 ms) to follow-up (111 +/- 32 ms, P = 0.04). The improvement in NYHA after CRT was significantly associated with baseline (123)I-MIBG H/M washout rate (r = 0.65, P = 0.03). The improvement in LVESV index was associated with baseline (123)I-MIBG delayed H/M ratio (r =-0.67, P = 0.02) and H/M washout rate (r = 0.65, P = 0.03).
CONCLUSION: After CRT, improvements in cardiac symptoms and LV function were accompanied by rebalanced cardiac autonomic control as measured by (123)I-MIBG and HRV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18479331      PMCID: PMC2756798          DOI: 10.1111/j.1540-8167.2008.01190.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  38 in total

1.  Cardiac resynchronization therapy improves heart rate variability in patients with symptomatic heart failure.

Authors:  Philip B Adamson; Karen J Kleckner; Warren L VanHout; Sriram Srinivasan; William T Abraham
Journal:  Circulation       Date:  2003-07-14       Impact factor: 29.690

2.  Sustained sympathoinhibitory effects of cardiac resynchronization therapy in severe heart failure.

Authors:  Guido Grassi; Antonio Vincenti; Roberta Brambilla; Fosca Quarti Trevano; Raffaella Dell'Oro; Antonio Cirò; Giuseppe Trocino; Antonella Vincenzi; Giuseppe Mancia
Journal:  Hypertension       Date:  2004-09-20       Impact factor: 10.190

3.  Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure.

Authors:  Shu Kasama; Takuji Toyama; Hisao Kumakura; Yoshiaki Takayama; Shuichi Ichikawa; Tadashi Suzuki; Masahiko Kurabayashi
Journal:  J Nucl Med       Date:  2003-06       Impact factor: 10.057

4.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.

Authors:  J N Cohn; T B Levine; M T Olivari; V Garberg; D Lura; G S Francis; A B Simon; T Rector
Journal:  N Engl J Med       Date:  1984-09-27       Impact factor: 91.245

5.  Myocardial imaging with a radioiodinated norepinephrine storage analog.

Authors:  D M Wieland; L E Brown; W L Rogers; K C Worthington; J L Wu; N H Clinthorne; C A Otto; D P Swanson; W H Beierwaltes
Journal:  J Nucl Med       Date:  1981-01       Impact factor: 10.057

6.  Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function.

Authors:  J C Sisson; D M Wieland; P Sherman; T J Mangner; M C Tobes; S Jacques
Journal:  J Nucl Med       Date:  1987-10       Impact factor: 10.057

7.  Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial.

Authors:  James B Young; William T Abraham; Andrew L Smith; Angel R Leon; Randy Lieberman; Bruce Wilkoff; Robert C Canby; John S Schroeder; L Bing Liem; Shelley Hall; Kevin Wheelan
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

8.  Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: implications for clinical studies.

Authors:  G Aernout Somsen; Hein J Verberne; Eric Fleury; Alberto Righetti
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

9.  Desipramine attenuates loss of cardiac sympathetic neurotransmitters produced by congestive heart failure and NE infusion.

Authors:  Chang-seng Liang; Akito Yatani; Yoshihiro Himura; Michihiro Kashiki; Susanne Y Stevens
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-01-23       Impact factor: 4.733

10.  Efficacy of carvedilol treatment on cardiac function and cardiac sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with metoprolol therapy.

Authors:  Takuji Toyama; Hiroshi Hoshizaki; Ryotaro Seki; Naoki Isobe; Hitoshi Adachi; Shigeto Naito; Shigeru Oshima; Koichi Taniguchi
Journal:  J Nucl Med       Date:  2003-10       Impact factor: 10.057

View more
  8 in total

Review 1.  Role of cardiac MRI and nuclear imaging in cardiac resynchronization therapy.

Authors:  Niti R Aggarwal; Matthew W Martinez; Bernard J Gersh; Panithaya Chareonthaitawee
Journal:  Nat Rev Cardiol       Date:  2009-11-03       Impact factor: 32.419

2.  123I-meta-Iodobenzylguanidine Imaging in Patients with Cardiac Resynchronization Therapy: Results are Intriguing, but Unknowns Remain.

Authors:  Anisiia Doytchinova; Myron C Gerson
Journal:  J Nucl Cardiol       Date:  2018-08-01       Impact factor: 5.952

Review 3.  Cardiac molecular imaging to track left ventricular remodeling in heart failure.

Authors:  Jamshid Shirani; Amitoj Singh; Sahil Agrawal; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2016-08-01       Impact factor: 5.952

Review 4.  Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeutics.

Authors:  Kalyanam Shivkumar; Olujimi A Ajijola; Inder Anand; J Andrew Armour; Peng-Sheng Chen; Murray Esler; Gaetano M De Ferrari; Michael C Fishbein; Jeffrey J Goldberger; Ronald M Harper; Michael J Joyner; Sahib S Khalsa; Rajesh Kumar; Richard Lane; Aman Mahajan; Sunny Po; Peter J Schwartz; Virend K Somers; Miguel Valderrabano; Marmar Vaseghi; Douglas P Zipes
Journal:  J Physiol       Date:  2016-06-14       Impact factor: 5.182

5.  Relationship of left ventricular global longitudinal strain with cardiac autonomic denervation as assessed by 123I-mIBG scintigraphy in patients with heart failure with reduced ejection fraction submitted to cardiac resynchronization therapy : Assessment of cardiac autonomic denervation by GLS in patients with heart failure with reduced ejection fraction submitted to CRT.

Authors:  Madalena Coutinho Cruz; Ana Abreu; Guilherme Portugal; Helena Santa-Clara; Pedro S Cunha; Mario M Oliveira; Vanessa Santos; Luís Oliveira; Pedro Rio; Inês Rodrigues; Luís A Morais; Rui C Ferreira; Miguel M Carmo
Journal:  J Nucl Cardiol       Date:  2017-12-05       Impact factor: 5.952

Review 6.  Cardiac sympathetic innervation and cardiac resynchronization therapy.

Authors:  A M Scholtens; A J A T Braat; A Tuinenburg; M Meine; H J Verberne
Journal:  Heart Fail Rev       Date:  2014-09       Impact factor: 4.214

Review 7.  Evaluating presynaptic and postsynaptic innervation in heart failure.

Authors:  Grace P Chen; James H Caldwell
Journal:  Curr Cardiol Rep       Date:  2009-03       Impact factor: 2.931

8.  The relation between cardiac 123I-mIBG scintigraphy and functional response 1 year after CRT implantation.

Authors:  D O Verschure; E Poel; G De Vincentis; V Frantellizzi; K Nakajima; O Gheysens; J R de Groot; H J Verberne
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-01-01       Impact factor: 6.875

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.